Clinical evidence of hepatoprotection induced by ursodeoxycholic acid.
Ursodeoxycholic-acid (UDCA) was introduced to the clinical practice as an effective agent for the dissolution of gallstones. The efficacy of UDCA was proved recently in the treatment of patients with chronic cholestatic liver disease. We demonstrate the hepatoprotective effect of UDCA in a patient with chronic cholestatic liver disease. A sixty-nine years old male patient was admitted to our department with severe jaundice. The laboratory and radiologic examinations revealed significant cholestasis without any morphological alterations. Among the serological tests the anti-HCV antibody was positive. Based on these findings and anamnestic data (no blood transfusion and/or operation), sporadic chronic C virus hepatitis was assumed with dominant cholestasis. The corticosteroid therapy even in high doses was ineffective, the liver function parameters worsened. Later UDCA (Ursofalk, Falk Pharma) was given at a dose of 250 mg three times daily. Clinical improvement was seen after the first week of UDCA treatment. The patient's complaints relieved parallel with decrease of serum bilirubin, gamma-glutamyl transferase and transaminase levels. These parameters showed further decrease during the treatment.
Vincze
A
A
First Department of Medicine, Medical University of Pecs, Hungary.
Patty
I
I
Jávor
T
T
Pár
A
A
D000368:Aged; D001663:Bilirubin / Q000097:blood; D002780:Cholestasis, Intrahepatic / Q000188:drug therapy* / Q000201:enzymology / Q000209:etiology; D002908:Chronic Disease; D006508:Hepatitis Antibodies / Q000032:analysis; D006526:Hepatitis C / Q000150:complications / Q000276:immunology; D006801:Humans; D008111:Liver Function Tests; D008297:Male; D011239:Prednisolone / Q000627:therapeutic use; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use*
D006508:Hepatitis Antibodies; D014580:Ursodeoxycholic Acid; D011239:Prednisolone; D001663:Bilirubin